THESSALONIKI, Greece — A brand new drug therapy for sufferers with Sort 2 diabetes seems to do a greater job of controlling blood sugar ranges and aiding in weight reduction than the favored treatment semaglutide. Greek researchers found that the drug tirzepatide outperforms semaglutide — out there underneath model names Ozempic and Wegovy.
Each semaglutide and tirzepatide are used within the therapy of Sort 2 diabetes. Whereas semaglutide is already approved for weight loss administration, tirzepatide is making its method in that route, with producers submitting functions for its approval for this function.
Relatively than conducting a brand new experiment, researchers at Aristotle College of Thessaloniki aggregated outcomes from 22 particular person research, a way known as a meta-analysis, to attract conclusions on the effectiveness and safety of the two drugs. This meta-analysis concerned information from 18,472 sufferers recognized with Sort 2 diabetes.
The important thing measure on this analysis was HbA1c (glycated haemoglobin). HbA1c is an indicator used to measure long-term blood sugar management.
Of their findings, researchers found that sufferers who took tirzepatide witnessed a higher discount of their HbA1c ranges and skilled more weight loss in comparison with those that took semaglutide. Tirzepatide’s 15 mg dosage resulted in a median weight lack of 10.96 Kg, whereas the two.0 mg dosage of semaglutide led to a median weight lack of 5.24 Kg (11.55 kilos).
Which means, on common, people taking tirzepatide 15 mg lost 5.72kg (12.6 lbs) greater than these on semaglutide 2.0 mg.
Are there side-effects?
Whereas each medicine are efficient, they weren’t with out side-effects. In comparison with a placebo (a pretend drug with no therapeutic impact), all doses of each medicine had an elevated threat for gastrointestinal points. Excessive doses of tirzepatide (15 mg) had a notable affiliation with the next threat of nausea and vomiting in comparison with sure doses of semaglutide.
“In individuals with Sort 2 diabetes, tirzepatide 5, 10, and 15 mg had been extra efficacious in lowering HbA1c in comparison with semaglutide 0.5, 1.0, and a pair of.0 mg, respectively,” researchers say in a media release. “Tirzepatide additionally was additionally more practical for weight reduction than semaglutide, with a bigger weight-loss impact at increased doses. Excessive-dose tirzepatide (15 mg) was related to elevated threat for vomiting versus low- and medium-dose semaglutide.”
The findings will likely be introduced on the annual assembly of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany, in October.
You may additionally be thinking about:
